|
| |
Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
|
Published: Jan 2012 | Pages: 160 | Pub ID: MM1326690845 |
|
|
|
 |
There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells also have value as a research tool, as their in vitro study would allow scientists to learn more about the function of various organs and the development of particular diseases; stem cells may also eventually permit drug developers to test emerging therapies on diseased cells.
For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the pharmaceutical market. New scientific developments and recent changes in the U.S. Federal government\'s policy towards stem cells have made this potential more relevant. Kalorama Information has tackled the question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:
- Stem Cells in Drug Development
- Stem Cells in Cord Blood Banking
- Stem Cell Therapeutics
Stem cell therapeutics potentials are provided, broken down by disease:
- Cardiovascular disease
- Lung disease
- Tooth disease
- Arthritis
- Wrinkles/aging skin
- Incontinence
- Osteoporosis
- Diabetes
- Cancer
- Bladder disease
- Infertility
- Orthopedics
- Alzheimer’s disease
- Burns (severe)
- Lupus
- Parkinson’s disease
- Liver failure
- Multiple sclerosis
- Critical limb ischemia
- Intestinal disease
- Sickle cell disease
- Multiple myeloma
- NH Lymphoma
- Leukemia
The following trends are discussed in this report:
- Ethical Questions
- U.S. – State and Federal Initiatives
- Research Funding
- Cord Blood Initiatives
- International Initiatives
- Stem Cell Patents
- Other Healthcare Regulations
|
|
| By: Kalorama Information |
|
|
| |
|
|
|
US Office
India Office